MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2019 International Congress

    Continuous circadian intracerebroventricular administration of anaerobic dopamine: A new therapeutic concept for Parkinson’s disease?

    C. Moreau, C. Laloux, C. Lachaud, E. Pioli, Q. Li, P. Pascal, L. Defebvre, R. Bordet, E. Bezard, M. Fisichella, D. Devos (Lille, France)

    Objective: We aim to overcome these challenges by demonstrating that continuous i.c.v. of Anaerobic-dopamine (A-dopamine,Patent #WO2015173258 A1) close to the striatum is a feasible and…
  • 2019 International Congress

    Effect of gastrointestinal surgery on the pharmacokinetics of levodopa in Parkinson’s disease

    N. Miyaue, M. Nomoto, H. Yabe, Y. Yamanishi, S. Tada, R. Ando, M. Kubo, M. Nagai (Ehime, Japan)

    Objective: The aim of this study is to evaluate the pharmacokinetics of levodopa in patients with Parkinson’s disease (PD) who underwent gastrointestinal surgery. Background: Levodopa…
  • 2019 International Congress

    Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials

    R. Hauser, O. Rascol, W. Poewe, J. Ferreira, A. Lees, O. Klepitskaya, G. Liang, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Tampa, FL, USA)

    Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients, the ability of opicapone (OPC) to act as levodopa-sparing agent. Background: OPC, a once-daily COMT inhibitor,…
  • 2019 International Congress

    Multi-kinase Abelson (c-Abl) and Discoidin Domain Receptors (DDR1/2) inhibitors, Nilotinib, alters CSF soluble TREM2 (sTREM2) in individuals with Parkinson’s Disease

    F. Pagan, M. Hebron, B. Wilmarth, Y. Torres-Yaghi, E. Mundel, N. Yusuf, C. Moussa (Washington, DC, USA)

    Objective: Our objective was to examine the effects of broad-based tyrosine kinase inhibition in cerebrospinal fluid biomarkers. Background: Nilotinib is a broad-based tyrosine kinase inhibitor…
  • 2019 International Congress

    Results of community pharmacist-led structured medication reviews in Parkinson’s Disease

    N. Oonk, P. Oude Avenhuis, K. Movig, K. Koehorst-Ter Huurne, WH. Nijmeijer, M. van Kesteren-Biegstraaten, J. Vd Palen, L. Dorresteijn (Enschede, Netherlands)

    Objective: To obtain insight in the process of community pharmacist-led structured medication reviews in patients with Parkinson’s disease (PD), by evaluating medication modifications and recommendations, and…
  • 2019 International Congress

    Long-term levodopa-carbidopa intestinal infusion in Parkinson’s disease: survival and mortality

    CA. Artusi, R. Balestrino, G. Imbalzano, S. Bortolani, S. Tuttobene, E. Montanaro, M. Zibetti, L. Lopiano (Torino, Italy)

    Objective: We sought to analyze the mortality and the causes of death of 105 patients with Parkinson disease (PD) treated with levodopa-carbidopa intestinal gel (LCIG)…
  • 2019 International Congress

    The Effect of Gocovri on Motor Aspects of Experiences of Daily Living: Analyses of MDS-UPDRS Part II Data from a Phase 3 Program

    R. Hauser, D. Kremens, D. Chernick, R. Patni, J. Hubble (Tampa, FL, USA)

    Objective: To assess the impact of Gocovri® (amantadine) extended release capsules on motor aspects of experiences of daily living in PD patients. Background: Gocovri is…
  • 2019 International Congress

    The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program

    R. Pahwa, C. Tanner, L. Zhang, R. Johnson, C. Leroue, R. Patni (Kansas City, KS, USA)

    Objective: To assess patient outcomes and adverse events in Parkinson’s disease (PD) patients treated with Gocovri® (amantadine) extended release capsules at bedtime for dyskinesia, by…
  • 2019 International Congress

    Preclinical profile of dopamine D1PAM: A novel mechanism in clinical development for Lewy Body dementia

    K. Svensson, J. Beck, J. Hao, J. Schaus, X. Wang, B. Heinz, S. Mitchell, K. Wafford, C. Yang, L. Zhang, S. Castner, G. Williams, H. Marston, R. Bruns (Indianapolis, IN, USA)

    Objective: Introduce the mechanism of action for dopamine D1 positive allosteric modulator (D1PAM) as a new target for neuropsychiatric disorders. Describe the preclinical profile of…
  • 2019 International Congress

    Parkinson Kinetigraph – does it change the management of PD patients?

    F. Bergquist, A. Cvejtkovic, AC. Sjöström, S. Wallerstedt (Gothenburg, Sweden)

    Objective: This pragmatic randomized open trial evaluated if the information from a Parkinson Kinetigraph (PKG) recording changed the management of PD patients at a visit…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 34
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Comorbid Normal Pressure Hydrocephalus with Parkinson’s disease: a call for clinical awareness
  • Common mistakes in the MoCA test in patients with Parkinson’s Disease in Kyrgyzstan
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley